The Centers for Disease Control and Prevention Sept. 22 recommended the first maternal vaccine to protect newborns from severe illness from respiratory syncytial virus, the leading cause of hospitalization for U.S. infants. In a clinical study, the Pfizer vaccine (Abrysvo) reduced the risk of hospitalization by 57% in the first six months after birth. CDC recommends receiving one dose of the vaccine during weeks 32-36 of pregnancy.

“I encourage parents to talk to their doctors about how to protect their little ones against serious RSV illness, using either a vaccine given during pregnancy, or an RSV immunization given to your baby after birth,” said CDC Director Mandy Cohen, M.D.

The Food and Drug Administration approved the vaccine in August. It is currently available in some U.S. locations and should become more available in the coming weeks, CDC said.

Related News Articles

Headline
The creators of Grady Health System’s Teen Experience and Leadership Program describe how providing hands-on internships for local teens is helping to build…
Headline
The Patient-Centered Outcomes Research Institute Nov. 28 awarded $80.5 million to support comparative clinical effectiveness studies on the health care and…
Headline
Crysta Meekins, a program manager for AHA’s Institute for Diversity and Health Equity, shares four takeaways on how to provide equitable, culturally competent…
Headline
Michael Warren, M.D., associate administrator for the Health Resources and Services Administration’s Maternal and Child Health Bureau, discusses why the agency…
Blog
The statistics around Black maternal health in the U.S. remain grim. Data from the Centers for Disease Control and Prevention show that Black women are two-to-…
Headline
The Centers for Medicare & Medicaid Services Nov. 8 began displaying its “birthing friendly” hospital designation on Medicare’s Care Compare website …